Open AccessIncreased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study
Author(s) -
Guillaume Cartron,
Rémi Letestu,
Caroline Dartigeas,
Mira Tout,
Beatrice Mahé,
Anne-Laure Gagez,
Emmanuelle Ferrant,
Boris Guiu,
Bruno Villemagne,
Letuan Phan,
Thérèse Aurran,
Frédérique OrsiniPiocelle,
Anne Banos,
Pierre Feugier,
Véronique Leblond,
Sophie de Guibert,
Olivier Tournilhac,
Jehan Dupuis,
Alain Delmer,
Valérie Rouille,
David Ternant,
Stéphane Leprêtre
Publication year - 2018
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.2017.182352
Subject(s) - rituximab , fludarabine , chronic lymphocytic leukemia , medicine , cyclophosphamide , leukemia , oncology , immunology , chemotherapy , lymphoma